Cost‐effectiveness of the diabetes remission clinical trial ( DiRECT )/Counterweight‐Plus weight management programme, based on 5‐year follow‐up
Authors' conclusion
The costs involved in achieving remissions from type 2 diabetes with the Counterweight-Plus diet programme were offset within 5 years through reduced healthcare resource use. Though remission may ultimately relapse, sustained weight loss brings other longer term health gains. The intervention, even using one-to-one face-to-face contacts rather than remote delivery, which is increasingly adopted, generated both health gains and cost-savings compared with current best practice.
Study context
- Population
- Participants of DiRECT with T2D
- Comparison
- Counterweight-Plus weight management programme vs current best practice
Methodological detailslifetime horizon, 5-year follow-up data, modelling assumed relapse of all in remission after a maximum of 10 years
- Lifetime horizon
- 5-year follow-up data
- Modelling assumed relapse of all in remission after a maximum of 10 years
Primary result
As reported in the abstract
Incremental QALYs with intervention
0.08
Saving per participant
£496
Further findings
Healthcare costs over 5 years
- Total (discounted) healthcare cost-savings (excluding intervention costs) per participant
- £2091
- Healthcare costs per annum lower per participant in intervention arm (p < 0.05)
- ~£480
- Total intervention cost per participant (95% CI: £1566, 1822)
- £1691
- Reduced hospital admissions accounted for the major part of the saving
Cost-savings and QALY gains over 5 years
- Cost-savings
- ~£400
- QALY gains
- 0.043
- Remission associated with significant improvement in quality of life
- Modelled
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →